91P - Potential biomarkers of response to DKK1 blockade with DKN-01 in combination with paclitaxel in advanced esophagogastric cancer (EGC) patients (pts)

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Drug Development
Oesophageal Cancer
Gastric Cancer
Translational Research
Presenter Dan Duda
Citation Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363
Authors D.G. Duda1, C. Sirard2
  • 1Radiation Oncology, Massachusetts General Hospital, 02114 - Boston/US
  • 2Clinical Development, Leap Therapeutics, Inc., 02141 - Cambridge/US

Abstract

Background

Overexpression of DKK1, a modulator of canonical WNT signaling, is frequently seen in malignant tumors and is often associated with worse survival. Preclinical studies have shown that DKK1 can augment tumorigenesis by promoting angiogenesis as well as enhancing tumor-associated immunosuppression. In this Phase I trial, DKN-01 (a humanized IgG4 monoclonal antibody against DKK1) showed encouraging early efficacy signals when combined with paclitaxel (DP) in EGC pts (Strickler et al., GI ASCO 2017). We performed correlative studies of plasma biomarkers of angiogenesis and inflammation in these pts.

Methods

Blood samples were collected from 34 patients treated with DP at baseline, and then weekly for 4 weeks (w). Plasma biomarkers were measured by multiplexed array for angiogenesis (bFGF, PIGF/PGF, sVEGFR1, sTIE-2, VEGF, VEGF-C, and VEGF-D) and inflammation (IFN-g, TNF-a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70 and IL-13) (Meso-Scale Discovery) and by ELISA for HGF and SDF-1a (R&D Systems). Biomarker changes were evaluated by Wilcoxon Sign-Rank test, and correlations with response using Kendall’s test values and with survival using two-sided Wald test in the Cox regression.

Results

Six of 34 EGC pts in this subset analysis (18%) had a PR and 11/34 (32%) showed SD with preliminary median PFS and OS of 13.7w and 28.4w, respectively. DP treatment induced significant and sustained increases in plasma IFN-g, IL-8, VEGF-D and decreases in IL-10 (all p  1 all time-points) and prolonged in pts with greater increases in IL-2 and VEGF-D after treatment.

Conclusions

Prospective plasma biomarker analyses showed that DP treatment changed biomarkers of systemic immunity and angiogenesis in EGC pts, and indicated potential associations between inflammation biomarkers and outcomes. These hypothesis-generating results will inform future prospective investigation of these plasma biomarkers as well as paired evaluation of tumor biopsies for this combination regimen.

Clinical trial identification

Clinical trial information: NCT02013154

Legal entity responsible for the study

Leap Therapeutics, Inc.

Funding

Leap Therapeutics, Inc.

Disclosure

D.G. Duda: Consultant fees from Bayer and research funding from Leap Therapeutics, Inc, Merrimack, Bristol-Myers Squibb and Bayer. C. Sirard: Employee of Leap Therapeutics, Inc. (salary and stock options for compensation).